CAPTION: Siemens Healthineers raises 2022 outlook on demand for COVID-19 tests. (picture alliance / NurPhoto)
Medical device company Siemens Healthineers raised its full-year outlook following robust sales in its second quarter, driven by higher-than-expected demand for the company's COVID-19 rapid antigen tests.
The German company said it had revised up its year-on-year revenue expectations for the fiscal year, which ends in September. It now expect growth between 5.5% and 7.5%, compared to the previous 3% to 5%.
The diagnostics segment achieved revenue growth of 37.2%. The company took in almost €680 million ($715 million) in revenue from the rapid coronavirus tests.
Overall, second quarter earnings before interest and taxes increased 47% over the prior-year period to €980 million. Net income rose 30% to €583 million.
Sales were only slightly impacted by coronavirus restrictions in China and supply chain disruptions, it said.
In addition to the rapid test business, Healthineers benefited from the acquisition of the US cancer specialist Varian.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
